It carefully examines several subtypes, including hormone receptor-positive (HR+), HER2-positive (HER2+), and triple-negative breast cancer (TNBC), recognizing the illness' fundamental variety. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.